MNKD
MannKind Corporation NASDAQ Listed Jul 28, 2004$3.55
Mkt Cap $1.1B
52w Low $2.23
30.8% of range
52w High $6.51
50d MA $2.72
200d MA $4.61
P/E (TTM)
142.0x
EV/EBITDA
77.4x
P/B
—
Debt/Equity
-9.3x
ROE
-11.5%
P/FCF
126.6x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$2.72
200d MA
$4.61
Avg Volume
5.7M
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
30930 Russell Ranch Road · Danbury, CA 91362 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.02 | -0.05 | -150.0% | 3.56 | -6.7% | -0.3% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.01 | -0.05 | -400.0% | 3.24 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% | — |
| Nov 5, 2025 | AMC | 0.01 | 0.03 | +200.0% | 6.06 | +1.2% | -5.9% | -1.2% | -3.7% | -3.1% | +0.0% | — |
| Aug 6, 2025 | AMC | 0.04 | 0.00 | -94.8% | 3.47 | +2.9% | -1.2% | +2.6% | -2.8% | +7.0% | +1.9% | — |
| May 8, 2025 | AMC | 0.03 | 0.04 | +33.3% | 4.63 | +0.2% | -1.5% | +5.5% | -1.9% | -3.2% | -0.2% | — |
| Feb 26, 2025 | AMC | 0.03 | 0.03 | +0.0% | 5.47 | +0.0% | -4.4% | +2.1% | -3.9% | +0.4% | +0.0% | — |
| Nov 7, 2024 | AMC | 0.06 | 0.04 | -33.3% | 7.39 | -5.4% | -0.5% | -1.8% | -1.9% | -1.7% | +0.9% | — |
| Aug 7, 2024 | AMC | -0.03 | 0.05 | +250.1% | 5.01 | +2.0% | +3.6% | -2.7% | +2.8% | -2.3% | +2.4% | — |
| May 8, 2024 | AMC | 0.03 | 0.04 | +53.8% | 4.40 | +3.4% | -2.0% | +0.2% | +2.1% | +2.0% | -1.1% | — |
| Feb 27, 2024 | AMC | — | 0.02 | — | 3.78 | +3.2% | +3.7% | +4.8% | +9.5% | +3.3% | +2.2% | — |
| Nov 7, 2023 | AMC | 0.01 | 0.02 | +160.4% | 3.80 | +5.8% | -3.9% | -4.9% | -1.2% | +3.2% | +5.1% | — |
| Aug 7, 2023 | AMC | -0.01 | -0.02 | -47.2% | 4.60 | +8.7% | +18.5% | -2.0% | -0.9% | -0.8% | +0.4% | — |
| May 9, 2023 | AMC | -0.05 | -0.04 | +20.0% | 3.80 | +5.8% | +15.8% | -3.6% | -0.2% | +7.1% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.63 | $2.67 | +1.5% | +6.1% | -1.4% | +2.9% | +0.4% | -1.1% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $2.57 | $2.57 | +0.0% | +2.7% | +3.8% | +1.1% | -0.7% | +3.3% |
| Mar 5 | Wedbush | Maintains | Outperform → Outperform | — | $2.95 | $2.94 | -0.3% | -4.1% | -7.8% | +2.7% | -2.6% | +8.0% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 27 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.54 | $5.54 | +0.0% | -36.8% | -7.4% | +1.2% | -7.3% | -3.6% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.46 | $5.47 | +0.2% | +2.2% | +0.2% | +0.9% | +2.7% | -0.2% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.42 | $5.34 | -1.5% | -3.1% | +0.0% | -3.4% | -0.2% | -1.6% |
| Nov 11 | RBC Capital | Maintains | Outperform → Outperform | — | $5.42 | $5.34 | -1.5% | -3.1% | +0.0% | -3.4% | -0.2% | -1.6% |
| Oct 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.92 | +0.8% | +4.5% | +0.0% | +2.5% | +2.3% | +2.2% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.40 | +0.2% | +4.1% | -3.2% | +2.6% | -3.9% | -0.4% |
| Sep 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.34 | $5.48 | +2.6% | +3.7% | +0.5% | -1.1% | +1.1% | -2.7% |
| Sep 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.74 | $5.74 | +0.0% | -4.0% | -3.1% | +3.7% | +0.5% | -1.1% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $6.06 | +32.0% | +25.1% | -4.0% | -3.1% | +3.7% | +0.5% |
| Aug 26 | RBC Capital | Maintains | Outperform → Outperform | — | $3.90 | $4.12 | +5.6% | +4.4% | +11.1% | -0.7% | +2.2% | +25.1% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $3.47 | $3.57 | +2.9% | -1.2% | +2.6% | -2.8% | +7.0% | +1.9% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.08 | $4.10 | +0.5% | -0.5% | -2.5% | -3.5% | +1.3% | -2.3% |
| Jul 23 | RBC Capital | Maintains | Outperform → Outperform | — | $3.93 | $3.93 | +0.0% | +4.3% | -0.5% | -0.5% | -2.5% | -3.5% |
| Dec 19 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $5.94 | $6.30 | +6.1% | +6.1% | +8.7% | +2.5% | -4.0% | +2.2% |
| Aug 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.38 | $5.46 | +1.5% | +9.7% | +7.3% | -1.1% | -2.9% | +0.2% |
| May 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.40 | $4.55 | +3.4% | -2.0% | +0.2% | +2.1% | +2.0% | -1.1% |
| Mar 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.50 | $4.46 | -0.9% | -0.7% | +3.4% | +1.1% | +3.2% | -1.2% |
| Feb 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.78 | $3.90 | +3.2% | +3.7% | +4.8% | +9.5% | +3.3% | +2.2% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.74 | +1.1% | +3.2% | -4.7% | +1.9% | -3.8% | +0.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.29 | +0.8% | +0.4% | -0.6% | -3.6% | -2.0% | +0.6% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.60 | $5.00 | +8.7% | +18.5% | -2.0% | -0.9% | -0.8% | +0.4% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.42 | +0.5% | -3.6% | -0.2% | +7.1% | -3.1% | +3.6% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.41 | $5.55 | +2.6% | -0.6% | -1.9% | -8.5% | -0.4% | +1.2% |
| Nov 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.81 | $3.82 | +0.3% | +1.3% | +10.1% | +3.1% | -2.7% | +3.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.65 | -2.6% | -3.7% | +5.0% | +17.8% | -3.4% | -4.2% |
| Mar 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.38 | $3.49 | +3.3% | +8.6% | -1.1% | +4.7% | +1.3% | +2.6% |
| Mar 1 | Maxim Group | Downgrade | Hold → Sell | — | $2.93 | $2.84 | -3.1% | -3.1% | -0.4% | +0.4% | -1.1% | -1.4% |
| Nov 1 | Maxim Group | Downgrade | Buy → Hold | — | $3.29 | $3.28 | -0.3% | -8.5% | +7.3% | +0.9% | -0.9% | +0.6% |
| Nov 16 | Griffin Securities | Downgrade | Buy → Neutral | — | $12.20 | $11.45 | -6.1% | -7.4% | +0.0% | +3.1% | +3.4% | +2.5% |
| Nov 4 | RBC Capital | Downgrade | Outperform → Underperform | — | $16.15 | $15.25 | -5.6% | -7.4% | -6.7% | +2.9% | -8.4% | -12.5% |
| Sep 9 | Piper Sandler | Downgrade | Neutral → Underweight | — | $20.35 | $18.60 | -8.6% | -10.1% | +2.5% | -1.3% | -3.5% | +0.8% |
| Sep 9 | PiperJaffray | Downgrade | Neutral → Underweight | — | $20.35 | $18.60 | -8.6% | -10.1% | +2.5% | -1.3% | -3.5% | +0.8% |
| May 11 | JP Morgan | Downgrade | Neutral → Underweight | — | $19.05 | $18.25 | -4.2% | -4.7% | +0.6% | -0.5% | +0.0% | +10.1% |
| Mar 3 | Goldman Sachs | Downgrade | Neutral → Sell | — | $33.20 | $30.60 | -7.8% | -7.2% | -3.6% | -3.5% | -4.5% | -2.4% |
| Jul 1 | MLV & Co. | Downgrade | Buy → Hold | — | $54.80 | $54.00 | -1.5% | -5.8% | -4.3% | +1.2% | -0.9% | -2.2% |
| May 14 | PiperJaffray | Upgrade | Underweight → Neutral | — | $32.90 | $33.30 | +1.2% | +6.5% | -1.1% | +1.3% | +5.3% | +2.4% |
| May 14 | Piper Sandler | Upgrade | Underweight → Neutral | — | $32.90 | $33.30 | +1.2% | +6.5% | -1.1% | +1.3% | +5.3% | +2.4% |
| Apr 2 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $21.00 | $38.75 | +84.5% | +66.4% | -0.9% | -0.9% | -8.0% | +3.5% |
| Mar 31 | Piper Sandler | Downgrade | Neutral → Underweight | — | $24.15 | $22.20 | -8.1% | -16.8% | +4.5% | +66.4% | -0.9% | -0.9% |
| Mar 31 | PiperJaffray | Downgrade | Neutral → Underweight | — | $24.15 | $22.20 | -8.1% | -16.8% | +4.5% | +66.4% | -0.9% | -0.9% |
| Sep 6 | Bank of America | Downgrade | Neutral → Underperform | — | $31.50 | $30.00 | -4.8% | -7.0% | +2.0% | +1.2% | -2.8% | -0.3% |
| Sep 6 | BofA Securities | Downgrade | Neutral → Underperform | — | $31.50 | $30.00 | -4.8% | -7.0% | +2.0% | +1.2% | -2.8% | -0.3% |
| Jun 7 | Bank of America | Downgrade | Buy → Neutral | — | $38.25 | $37.30 | -2.5% | -2.5% | +0.5% | +2.0% | -0.1% | -2.2% |
| Jun 7 | BofA Securities | Downgrade | Buy → Neutral | — | $38.25 | $37.30 | -2.5% | -2.5% | +0.5% | +2.0% | -0.1% | -2.2% |
No insider trades available.
Data updated apr 26, 2026 12:47pm
· Source: massive.com